#NewAseBioMember | “AseBio is a key platform that brings together the main players in the Spanish biotechnology sector”

AseBio. What does your company's work bring to the table and what is its strength?

Jordi Mestre. At Melius Organics, we drive molecular innovation by exploring and expanding the chemical space into high-value regions for the development of better active pharmaceutical ingredients. Our chemical expertise spans various areas such as carbohydrates, amino acids, and fluorinated compounds, allowing us to deliver innovative products that others cannot offer. These capabilities are reflected in our two complementary business lines:

• Product catalog: We specialize in functionalization reagents and molecular fragments designed for research and development of new active ingredients. We particularly focus on chemical spaces with high potential in medicinal chemistry that are currently underexplored or underrepresented in the market.
• Synthesis services: We support companies and research centers that require high-value-added molecules for their projects. Our services include custom synthesis, lead optimization, and preparation of reference standards, such as metabolites and stable isotopes, among other specialized molecules.

AseBio. What is AseBio for you?

Jordi Mestre. AseBio is a key platform that brings together the main players in the Spanish biotechnology sector, enabling the exchange of needs, experiences, and perspectives. It serves as a modern agora where the future of the sector is debated, and mutual understanding, collaboration, and synergies are fostered.

Moreover, AseBio plays a fundamental role in aligning technology, market dynamics, and the regulatory framework, thus creating a favorable environment for the growth and consolidation of biotechnology in our country.

AseBio. When did you first hear about AseBio?

Jordi Mestre. As Melius Organics increasingly focused its activity on providing synthetic chemistry support to specialized groups in research centers and hospitals, we began looking for events where we could meet institutions of this profile. In that context, we came across BioSpain, an event that introduced us to AseBio and its strategic role as a key connector within Spain’s biotech ecosystem.

AseBio. What do you expect from being part of an association like AseBio?

Jordi Mestre. We hope that our participation in AseBio will help us understand and anticipate the main technological trends shaping the biotech sector. We also aim to connect with R&D actors from different areas who could benefit from complementing their expertise with our synthetic chemistry capabilities. Additionally, we are keen to actively participate in forums where current and future challenges of the sector are discussed, covering scientific, technological, regulatory, and market-related topics.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Jordi Mestre. One of the major challenges facing the biotech sector is achieving more effective technology transfer from the public sector. Despite the high scientific level of our research institutions, it remains difficult to turn that knowledge into applied innovation. To overcome this, it is essential to promote a more structured and continuous public-private collaboration that facilitates the joint development of impactful solutions.

In addition, the sector's growth depends on having a regulatory framework that is agile and innovation-friendly, one that does not hinder the creation and consolidation of startups but rather supports and accelerates their development.